Diligence memo · auto-generated · as of July 2, 2026
L.E.A.F. Pharmaceuticals LLC
L.E.A.F. Pharmaceuticals LLC looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
L.E.A.F. Pharmaceuticals LLC operates in Pharmaceuticals, based in Gulph Mills.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
L.E.A.F. Pharmaceuticals LLC has raised $40M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $40M on 2017-08-04.
Most recent recorded round closed around 2017-08-04.
Valuation (modeled)modeled
Provath models L.E.A.F. Pharmaceuticals LLC at approximately $1.4B (range $131M–$3.7B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.61× the median modeled value of Series C Pharmaceuticals companies in 2016–2018 (32 peers) — value vs value, same stage and era. Issuer reports $1M–$5M revenue while modeled below niche peers.
Financing rhythm & timingmixed
Last raise 8.9 yr ago; this sector typically re-raises about every 13 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 78% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 92% of those peers.
Closest niche peers: Amplyx Pharmaceuticals, Inc., Ligand Pharmaceuticals Inc, Homology Medicines, Inc., KSQ Therapeutics, Inc., TP Therapeutics, Inc..
Peoplefiled
4 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.